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ABSTRACT
Objectives: Some targeted therapies have improved
survival and overall quality of cancer care generally, but
these increasingly expensive medicines have led to
increases in pharmaceutical expenditure. This study
examined trends in use and expenditures of
antineoplastic agents in Taiwan, and estimated market
shares by prescription volume and costs of targeted
therapies over time. We also determined which cancer
types accounted for the highest use of targeted
therapies.
Design: This is a retrospective observational study
focusing on the utilisation of targeted therapies for
treatment of cancer.
Setting: The monthly claims data for antineoplastic
agents were retrieved from Taiwan’s National Health
Insurance Research Database (2009–2012).
Main outcome measures: We calculated market
shares by prescription volume and costs for each class
of antineoplastic agent by cancer type. Using a time
series design with Autoregressive Integrated Moving
Average (ARIMA) models, we estimated trends in use
and costs of targeted therapies.
Results: Among all antineoplastic agents, use of
targeted therapies grew from 6.24% in 2009 to
12.29% in 2012, but their costs rose from 26.16% to
41.57% in that time. Monoclonal antibodies and
protein kinase inhibitors contributed the most
(respectively, 23.84% and 16.12% of costs for
antineoplastic agents in 2012). During 2009–2012,
lung (44.64% of use; 28.26% of costs), female breast
(16.49% of use; 27.18% of costs) and colorectal
(12.11% of use; 13.16% of costs) cancers accounted
for the highest use of targeted therapies.
Conclusions: In Taiwan, targeted therapies are
increasingly used for different cancers, representing a
substantial economic burden. It is important to
establish mechanisms to monitor their use and
outcomes.
INTRODUCTION
Cancer is a major public health issue glo-
bally. Approximately 7.4 million people die
of cancer each year worldwide, which
accounts for 13% of all-cause mortality, and
this percentage is expected to increase.1 2 In
Taiwan, cancer is a leading cause of mortality
and the annual number of patients with
cancer has been growing.3 In 2011, ∼92 682
individuals were diagnosed with cancer
(male: 56%, female: 44%). Most common
cancers in Taiwan were female breast cancer,
colorectal cancer, liver cancer, lung cancer
and prostate cancer. In the same year,
∼42 559 patients died of cancer (male: 64%,
female: 36%), accounting for 28% of all
deaths. Major cancers causing mortality were
lung cancer, liver cancer, colorectal cancer,
female breast cancer and oral/pharyngeal
cancer.3
Cancer care has improved substantially and
the average life expectancy has increased in
the past two decades, due to preventative
strategies,4 early diagnosis,5 advances in
medical technologies (including surgery and
medications)6 and clinical management.
Strengths and limitations of this study
▪ This is the first study to examine the national
trend in use and costs of targeted therapies for
treatment of cancer in Taiwan.
▪ We also determined which cancer types
accounted for the highest use of targeted therap-
ies in Taiwan, from 2009 to 2012.
▪ Data were retrieved from Taiwan’s National
Health Insurance Research Database with nearly
99% of the Taiwanese population (around 23
million residents) enrolled and 97% of hospitals
and clinics throughout the country included.
▪ A time series design with Autoregressive
Integrated Moving Average (ARIMA) models was
used in this study, to estimate the trends in
market shares by prescription volume and costs
of targeted therapies.
▪ Owing to the lack of patient-level data, this study
did not investigate the use of combination treat-
ments; these need to be examined in future
studies.
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Traditionally, chemotherapies are the main medicines for
cancer. But these drugs are not speciﬁc to the target, and
therefore often cause serious adverse effects including
neutropaenia, anaemia and thrombocytopaenia.7 In the
last decade, however, many new anticancer drugs, so
called targeted therapies,8 have become available. These
drugs differ from standard chemotherapy in that they
target speciﬁc vulnerable nodes in molecular pathways;9 10
thus, they are generally less toxic than traditional che-
motherapies.11 For some cancers, targeted therapies are
becoming the main treatments, for example, trastuzumab
for early-stage and human epidermal growth factor recep-
tor 2 (HER2) positive metastatic breast cancer.12 13
Dozens of targeted therapies have become available in
recent years and many are in the drug development pipe-
line.14 While some have demonstrated improvements in
progression-free survival, other agents have provided
minimal or no gains in overall survival; for instance, sora-
fenib, sunitinib, temsirolimus, everolimus, bevacizumab,
pazopanib and axitinib for renal cell cancer.15
Changes in the cancer treatment paradigm are accom-
panied by signiﬁcant economic consequences. Targeted
therapies are expensive, typically costing from US$4500
to >US$10 000 per treatment month, even if they dem-
onstrate only improvements in progression-free survival
without marked gains in overall survival.15–20 The
increasing costs of new targeted cancer therapies
have risen 10 times during the last decade.21 Given the
number of new cancer medicines in development and
likely continual increases in drug prices, pricing of new
anticancer drugs is a real concern for accessibility and
affordability across all countries.15 22 23 Some have sug-
gested that a minimum of improvement in median sur-
vival of at least 3–6 months by new cancer medicines
compared with current standards is required for the new
agent to be considered as advanced and funded at
higher prices.24 Furthermore, because of the much higher
costs of targeted therapies compared with conventional
chemotherapy—while the number of eligible patients (due
to molecular subtyping) for individual agents is generally
small—in aggregate, costs of targeted therapies as a group
is an important contributor to growing expenditures for
cancer treatments and an important issue of sustainability
for all healthcare systems.25–27
Owing to limited ﬁnancial resources, patient access to
targeted therapies has been a struggle in many coun-
tries.28 Many countries have different ways to kerb the
growth of pharmaceutical expenditures in general.
Examples include formal health technology assessment
(for instance, economic evaluation of new drugs is
required by many payers/policymakers such as the
National Institute for Health and Care Excellence in the
UK29 30 and Pharmaceutical Beneﬁts Advisory
Committee in Australia31 32 to select drugs for coverage),
pricing tools such as reference pricing33 and high
patient cost-sharing (co-payments, co-insurance).34 To
deal with high drug costs and imperfect evidence at the
time of marketing approval, many countries are
increasingly adopting patient access schemes (also
known as managed entry agreements or risk-sharing
arrangements) to enable patient access to needed medi-
cines, while ensuring that ﬁnancing systems are sustain-
able.35 36 The performance of managed entry
agreements, however, is largely unknown because most
have not been evaluated.33 Major challenges at present
for many health systems include determining what pro-
portion of the healthcare budget should be allocated for
treatment of cancer, including budget for targeted ther-
apies, and designing and implementing new models for
pricing, reimbursement, funding and utilisation deci-
sions for cancer medicines.37
In Taiwan, economic evaluation has, since 2007, been
part of the health technology assessment to evaluate
new drugs, to determine decisions for coverage by the
National Health Insurance (NHI).38 39 In addition, prior
authorisation is required for many cancer medicines,
especially for targeted therapies with high reimburse-
ment prices. An application for prior authorisation can
be made to the NHI system, and the drug will be reim-
bursed if authorisation is given.40 For instance, accord-
ing to ‘Directions of Drug Restricted Beneﬁt for
National Health Insurance’, two targeted therapies, geﬁ-
tinib and erlotinib, for treatment of lung cancer, have
been reimbursed since 2004 and 2007, respectively. In
the beginning, both were restricted to be used as third-
line treatment, that is, patients must ﬁrst have been
treated with platinum and docetaxel or paclitaxel
chemotherapy, and must have had locally advanced or
metastatic adenocarcinoma of the lung.41
Little is known about the utilisation and economic
impacts of targeted cancer therapies in Taiwan. The aim
of our longitudinal analyses was to address this gap by
examining the recent trend in utilisation and expendi-
tures of cancer treatments, including targeted therapies,
in Taiwan. We also identiﬁed which types of cancer
accounted for the highest use of targeted therapies.
METHODS
Data sources
Taiwan’s National Health Insurance Research Database
provided data for this study. The database contains infor-
mation from a nationwide, mandatory-enrolment and
single-payer healthcare system created in 1995. Nearly
99% of the Taiwanese population (around 23 million
residents) is enrolled and this system contracts with 97%
of hospitals and clinics throughout the country.42 The
NHI covers a wide range of prescription medicines, as
well as inpatient and outpatient medical services.43 All
monthly claims data—including details of prescription
and insurer spending—for antineoplastic agents,
between 2009 and 2012, were retrieved from Taiwan’s
National Health Insurance Research Database. The
cancer-related prescriptions were identiﬁed by
International Classiﬁcation of Diseases, Ninth edition
(ICD-9) diagnosis codes for cancer (codes 140–239).
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Table 1 Prescription volume of antineoplastic agents in Taiwan (2009–2012)
Drug class Drug name for patients with cancer
Number of prescriptions (market share by prescription volume)
2009 2010 2011 2012 2009–2012
N
Per
cent N
Per
cent N
Per
cent N
Per
cent
Growth rate
of N (%)
Growth rate of
market share
(%)
All antineoplastic agents 1 893 439 100 2 033 160 100 2 300 629 100 2 489 973 100 31.51
Targeted therapies 118 186 6.24 150 401 7.40 209 030 9.09 306 140 12.29 159.03 6.05
Monoclonal antibodies Rituximab, trastuzumab, cetuximab,
bevacizumab
52 073 2.75 68 595 3.37 102 074 4.44 144 234 5.79 176.98 3.04
Protein kinase inhibitors Imatinib, gefitinib, erlotinib, sunitinib, sorafenib,
dasatinib, nilotinib, temsirolimus, everolimus,
pazopanib
63 936 3.38 78 675 3.87 102 435 4.45 153 764 6.18 140.50 2.80
Other targeted therapy
agents
Bortezomib 2177 0.11 3131 0.15 4521 0.20 8142 0.33 274.00 0.21
Alkylating agents 125 811 6.64 132 109 6.50 147 076 6.39 148 654 5.97 18.16 −0.67
Nitrogen mustard
analogues
Cyclophosphamide, chlorambucil, melphalan,
ifosfamide, bendamustine
112 602 5.95 117 101 5.76 125 769 5.47 130 042 5.22 15.49 −0.72
Alkyl sulfonates Busulfan 301 0.02 279 0.01 318 0.01 255 0.01 −15.28 −0.01
Nitrosoureas Carmustine 250 0.01 218 0.01 263 0.01 321 0.01 28.40 0.00
Other alkylating agents Temozolomide, dacarbazine 12 658 0.67 14 511 0.71 20 726 0.90 18 036 0.72 42.49 0.06
Antimetabolites 911 611 48.15 965 096 47.47 1 076 871 46.81 1 143 596 45.93 25.45 −2.22
Folic acid analogues Methotrexate, pemetrexed 316 174 16.70 349 463 17.19 386 008 16.78 426 480 17.13 34.89 0.43
Purine analogues Mercaptopurine, cladribine, fludarabine 12 550 0.66 12 094 0.59 12 277 0.53 12 891 0.52 2.72 −0.15
Pyrimidine analogues Cytarabine, fluorouracil, tegafur, gemcitabine,
capecitabine, tegafur_combinations
582 887 30.78 603 539 29.68 678 586 29.50 704 225 28.28 20.82 −2.50
Plant alkaloids and other natural products 217 347 11.48 222 304 10.93 250 312 10.88 250 273 10.05 15.15 −1.43
Vinca alkaloids and
analogues
Vinblastine, vincristine, vinorelbine 84 009 4.44 85 659 4.21 88 135 3.83 88 377 3.55 5.20 −0.89
Podophyllotoxin
derivatives
Etoposide 28 864 1.52 30 188 1.48 32 990 1.43 34 587 1.39 19.83 −0.14
Taxanes Paclitaxel, docetaxel 104 474 5.52 106 457 5.24 129 187 5.62 127 309 5.11 21.86 −0.40
Cytotoxic antibiotics and related substances 140 168 7.40 140 697 6.92 145 663 6.33 146 796 5.90 4.73 −1.51
Actinomycines Dactinomycin 616 0.03 698 0.03 667 0.03 761 0.03 23.54 0.00
Anthracyclines and
related substances
Doxorubicin, daunorubicin, epirubicin,
idarubicin, mitoxantrone
99 422 5.25 101 826 5.01 107 177 4.66 106 499 4.28 7.12 −0.97
Other cytotoxic
antibiotics
Bleomycin, mitomycin 40 130 2.12 38 173 1.88 37 819 1.64 39 536 1.59 −1.48 −0.53
Other non-targeted
therapies
380 316 20.09 422 553 20.78 471 677 20.50 494 514 19.86 30.03 −0.23
Platinum compounds Cisplatin, carboplatin, oxaliplatin 254 636 13.45 286 260 14.08 304 437 13.23 306 659 12.32 20.43 −1.13
Sensitisers used in
photodynamic/radiation
therapy
Verteporfin 120 0.01 88 0.00 88 0.00 95 0.00 −20.83 0.00
Others Asparaginase, hydroxycarbamide, estramustine,
tretinoin, topotecan, irinotecan, mitotane,
arsenic trioxide
125 560 6.63 136 205 6.70 167 152 7.27 187 760 7.54 49.54 0.91
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Drugs of interest
We used the Anatomical Therapeutic Chemical (ATC)
classiﬁcation system developed by the WHO. We identi-
ﬁed all antineoplastic agents using ATC codes ‘L01’.
Antineoplastic agents were grouped into six classes,
based on the ATC system: (1) targeted therapies, includ-
ing monoclonal antibodies (rituximab, trastuzumab,
cetuximab), protein kinase inhibitors (imatinib, geﬁti-
nib, erlotinib, sunitinib, sorafenib, dasatinib, nilotinib,
temsirolimus, everolimus, pazopanib) and bortezomib;
these have all been used for the treatment of cancer in
Taiwan; (2) alkylating agents (including nitrogen
mustard analogues, alkyl sulfonates, nitrosoureas and
other alkylating agents); (3) antimetabolites (including
folic acid analogues, purine analogues and pyrimidine
analogues); (4) plant alkaloids and other natural pro-
ducts (including Vinca alkaloids and analogues, podo-
phyllotoxin derivatives and taxanes); (5) cytotoxic
antibiotics and related substances (including actinomy-
cines, anthracyclines and related substances and other
cytotoxic antibiotics) and (6) other antineoplastic agents
(including platinum compounds, sensitisers used in
photodynamic/radiation therapy and other antineoplas-
tic agents).
Measurements
To examine trends in use and costs of each class of
antineoplastic agent (including targeted therapies),
we calculated quarterly and yearly numbers of pre-
scriptions and costs from 2009 to 2012. Then, for
each class, we calculated the proportion of its use
and costs among total use and total costs of all anti-
neoplastic agents. For example, market share by pre-
scription volume for targeted therapies was estimated
by: number of prescriptions for targeted therapies
divided by total number of prescriptions for all anti-
neoplastic agents; and the market share by costs was
estimated by: costs of targeted therapies divided by
total costs of all antineoplastic agents. We also calcu-
lated cost per prescription for each class of antineo-
plastic agent.
To understand which cancers accounted for high use
of targeted therapies, we ﬁrst selected the 20 most
common types of cancer in Taiwan, based on prevalence
(see online supplementary appendix). We used the total
prescription volume and total costs for targeted therap-
ies in Taiwan as the denominator and conducted ana-
lyses using clinical indication of their use by type of
cancer.
Statistical analysis
To assess the quarterly trends in market shares by pre-
scription volume and costs of targeted therapies among
all antineoplastic agents, we used a time series design
with the Autoregressive Integrated Moving Average
(ARIMA) model, which was developed by Box and
Jenkins.44 The model is generally referred to as an
ARIMA(p, d, q) model where parameters p, d and q are
non-negative integers that refer to the order of the auto-
regressive, integrated and moving average parts of the
model, respectively. These models are ﬁtted to time
series data either to better understand the data or to
determine points in the series.45 We used the estimated
rates by ARIMA model for time series graphs. All ana-
lyses were carried out with SAS software, V.9.3 (SAS
Institute, Cary, North Carolina, USA).
RESULTS
Between 2009 and 2012, prescriptions for antineoplastic
agents grew 31.51% (an average rate of 10.5% increase
per year) (table 1). By class, prescriptions for alkylating
agents, antimetabolites, plant alkaloids and cytotoxic
antibiotics increased in number during this period, but
their market shares decreased: −0.67%, −2.22%,
−1.43% and −1.51%, respectively. In contrast, the
market share of targeted therapies grew from 6.24% in
2009 to 12.29% in 2012. Speciﬁcally, market shares of
monoclonal antibodies and protein kinase inhibitors
doubled, from 2.75% to 5.79% and from 3.38% to
Figure 1 The 2009–2012 trends in market shares by
prescription volume (A) and costs (B) for targeted therapies.
(A) Market share by prescription volume. (B) Market share by
costs. ARIMA, Autoregressive Integrated Moving Average.
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Table 2 Costs of antineoplastic agents in Taiwan (2009–2012)
Drug class
Drug name for patients
with cancer
Cost (market share by costs)
2009 2010 2011 2012 2009–2012
Cost (US$)
Per
cent Cost (US$)
Per
cent Cost (US$)
Per
cent Cost (US$)
Per
cent
Growth rate
of N (%)
Growth rate
of market
share (%)
All antineoplastic
agents
491 387 822 100 570 369 759 100 660 138 086 100 740 386 783 100 50.67
Targeted
Therapies
128 541 502 26.16 177 668 722 31.15 224 327 855 33.98 307 754 974 41.57 139.42 15.41
Monoclonal
antibodies
Rituximab, trastuzumab,
cetuximab, bevacizumab
71 869 602 14.63 104 739 673 18.36 137 951 386 20.90 176 477 405 23.84 145.55 9.21
Protein kinase
inhibitors
Imatinib, gefitinib, erlotinib,
sunitinib, sorafenib, dasatinib,
nilotinib, temsirolimus,
everolimus, pazopanib
52 651 186 10.71 67 484 747 11.83 79 001 874 11.97 119 383 796 16.12 126.74 5.41
Other targeted
therapy agents
Bortezomib 4 020 714 0.82 5 444 303 0.95 7 374 595 1.12 11 893 774 1.61 195.81 0.79
Alkylating agents 15 551 932 3.16 17 481 103 3.06 18 968 906 2.87 18 999 092 2.57 22.17 −0.60
Nitrogen
mustard
analogues
Cyclophosphamide,
chlorambucil, melphalan,
ifosfamide, bendamustine
4 495 217 0.91 4 897 936 0.86 4 878 608 0.74 4 261 046 0.58 −5.21 −0.34
Alkyl sulfonates Busulfan 374 465 0.08 454 805 0.08 460 163 0.07 488 410 0.07 30.43 −0.01
Nitrosoureas Carmustine 41 620 0.01 43 440 0.01 153 101 0.02 392 128 0.05 842.16 0.04
Other alkylating
agents
Temozolomide, dacarbazine 10 640 629 2.17 12 084 922 2.12 13 477 034 2.04 13 857 508 1.87 30.23 −0.29
Antimetabolites 96 951 076 19.73 117 122 829 20.53 128 199 087 19.42 131 805 930 17.80 35.95 −1.93
Folic acid
analogues
Methotrexate, pemetrexed 31 305 924 6.37 50 705 521 8.89 61 101 669 9.26 66 069 402 8.92 111.04 2.55
Purine
analogues
Mercaptopurine, cladribine,
fludarabine
304 010 0.06 265 754 0.05 365 404 0.06 311 619 0.04 2.50 −0.02
Pyrimidine
analogues
Cytarabine, fluorouracil,
tegafur, gemcitabine,
capecitabine,
tegafur_combinations
65 341 142 13.30 66 151 554 11.60 66 732 014 10.11 65 424 909 8.84 0.13 −4.46
Plant alkaloids
and other natural
products
79 509 189 16.18 72 920 907 12.78 84 694 476 12.83 86 583 703 11.69 8.90 −4.49
Vinca alkaloids
and analogues
Vinblastine, vincristine,
vinorelbine
20 326 687 4.14 22 006 619 3.86 23 924 553 3.62 25 170 345 3.40 23.83 −0.74
Podophyllotoxin
derivatives
Etoposide 2 164 352 0.44 1 643 415 0.29 1 651 811 0.25 1 579 203 0.21 −27.04 −0.23
Taxanes Paclitaxel, docetaxel 57 018 150 11.60 49 270 873 8.64 59 118 111 8.96 59 834 155 8.08 4.94 −3.52
Continued
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Table 2 Continued
Drug class
Drug name for patients
with cancer
Cost (market share by costs)
2009 2010 2011 2012 2009–2012
Cost (US$)
Per
cent Cost (US$)
Per
cent Cost (US$)
Per
cent Cost (US$)
Per
cent
Growth rate
of N (%)
Growth rate
of market
share (%)
Cytotoxic
antibiotics and
related substances
26 190 529 5.33 26 232 768 4.60 27 270 661 4.13 26 075 058 3.52 −0.44 −1.81
Actinomycines Dactinomycin 16 854 0.00 18 603 0.00 18 303 0.00 19 062 0.00 13.10 0.00
Anthracyclines
and related
substances
Doxorubicin, daunorubicin,
epirubicin, idarubicin,
mitoxantrone
24 489 365 4.98 24 531 634 4.30 25 576 627 3.87 24 215 313 3.27 −1.12 −1.71
Other cytotoxic
antibiotics
Bleomycin, mitomycin 1 684 311 0.34 1 682 531 0.29 1 675 731 0.25 1 840 682 0.25 9.28 −0.09
Other
non-targeted
therapies
144 643 593 29.44 158 943 430 27.87 176 677 101 26.76 169 168 026 22.85 16.96 −6.59
Platinum
compounds
Cisplatin, carboplatin,
oxaliplatin
50 363 294 10.25 53 988 423 9.47 52 077 277 7.89 35 697 261 4.82 −29.12 −5.43
Sensitisers used
in
photodynamic/
radiation therapy
Verteporfin 169 600 0.03 124 373 0.02 124 373 0.02 134 267 0.02 −20.83 −0.02
Others Asparaginase,
hydroxycarbamide,
estramustine, tretinoin,
topotecan, irinotecan,
mitotane, arsenic trioxide
94 110 699 19.15 104 830 634 18.38 124 475 451 18.86 133 336 498 18.01 41.68 −1.14
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6.18%, respectively. Figure 1A shows ARIMA regression
estimated quarterly trends in market share by prescrip-
tion volume for targeted therapies during the study
period.
Table 2 presents the costs for all and each type of anti-
neoplastic drug between 2009 and 2012. There was a
large growth in total costs of antineoplastic agents from
2009 to 2012 (an overall increase of 50.67%, an average
rate of 16.89% increase per year). By class, the yearly
market share by costs for alkylating agents, antimetabo-
lites, plant alkaloids and cytotoxic antibiotics, reduced
by 0.60%, 1.93%, 4.49% and 1.81%, from 2009 to 2012.
In contrast, annual costs of targeted therapies grew from
US$129 million (26.16% of all costs for antineoplastic
agents) in 2009 to US$308 million (41.57%) in 2012.
Speciﬁcally, the market share by costs for monoclonal
antibodies and protein kinase inhibitors increased from
14.63% to 23.84% and from 10.71% to 16.12%, respect-
ively. Figure 1B shows the ARIMA regression estimated
quarterly trend in market share by costs for targeted
therapies during the study period.
Table 3 shows the cost per prescription for each class
of antineoplastic agents between 2009 and 2012. We
found that, in 2012, targeted therapies had the highest
cost per prescription (US$1005), other antineoplastic
agents in descending order by cost per prescription
were plant alkaloids and other natural products
(US$346), other non-targeted therapies (US$342),
cytotoxic antibiotics and related substances (US$178),
alkylating agents (US$128) and antimetabolites (US
$115). There was about a 3-fold difference in cost per
prescription between targeted therapies, and plant
alkaloids and other natural products, and about a
10-fold difference between targeted therapies and
antimetabolites.
Figure 2A, B presents the distribution ratios of tar-
geted therapy use for 20 cancers during 2009–2012.
Table 4 shows the yearly distribution ratios of targeted
Table 3 Cost per prescription of antineoplastic agents in Taiwan (2009–2012)
Cost per prescription (US$)
Drug class Drug name for patients with cancer 2009 2010 2011 2012
All antineoplastic agents 260 281 287 297
Targeted therapies 1088 1181 1073 1005
Monoclonal antibodies Rituximab, trastuzumab, cetuximab, bevacizumab 1380 1527 1351 1224
Protein kinase inhibitors Imatinib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib,
nilotinib, temsirolimus, everolimus, pazopanib
823 858 771 776
Other targeted therapy
agents
bortezomib 1847 1739 1631 1461
Alkylating agents 124 132 129 128
Nitrogen mustard analogues Cyclophosphamide, chlorambucil, melphalan, ifosfamide,
bendamustine
40 42 39 33
Alkyl sulfonates Busulfan 1244 1630 1447 1915
Nitrosoureas Carmustine 166 199 582 1222
Other alkylating agents Temozolomide, dacarbazine 841 833 650 768
Antimetabolites 106 121 119 115
Folic acid analogues Methotrexate, pemetrexed 99 145 158 155
Purine analogues Mercaptopurine, cladribine, fludarabine 24 22 30 24
Pyrimidine analogues Cytarabine, fluorouracil, tegafur, gemcitabine,
capecitabine, tegafur_combinations
112 110 98 93
Plant Alkaloids and other Natural Products 366 328 338 346
Vinca alkaloids and
analogues
Vinblastine, vincristine, vinorelbine 242 257 271 285
Podophyllotoxin derivatives Etoposide 75 54 50 46
Taxanes Paclitaxel, docetaxel 546 463 458 470
Cytotoxic antibiotics and related substances 187 186 187 178
Actinomycines Dactinomycin 27 27 27 25
Anthracyclines and related
substances
Doxorubicin, daunorubicin, epirubicin, idarubicin,
mitoxantrone
246 241 239 227
Other cytotoxic antibiotics Bleomycin, mitomycin 42 44 44 47
Other non-targeted therapies 380 376 375 342
Platinum compounds Cisplatin, carboplatin, oxaliplatin 198 189 171 116
Sensitisers used in
photodynamic/radiation
therapy
Verteporfin 1413 1413 1413 1413
Others Asparaginase, hydroxycarbamide, estramustine, tretinoin,
topotecan, irinotecan, mitotane, arsenic trioxide
750 770 745 710
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therapy use by cancer type over time. Our results
showed that use and costs for targeted therapies differed
substantially between different types of cancer. During
2009–2012, targeted therapies were mostly used for
cancers of the lung and female breast, colorectal cancer,
lymphoma and leukaemia, in order of volume. These
ﬁve cancer types accounted for, respectively, 44.64%,
16.49%, 12.11%, 12.09% and 3.17% of prescriptions for
targeted therapies (together 88.5%); and 28.26%,
27.18%, 13.16%, 10.23% and 4.94% of costs for targeted
therapies (together 83.77%) among these 20 common
cancer types.
DISCUSSION
To the best of our knowledge, this is the ﬁrst study to
examine the national trend in use and costs of targeted
therapies for treatment of cancer in Taiwan. Our ﬁnd-
ings indicated that, compared with other classes of anti-
neoplastic drugs, use of targeted therapies, novel agents
for cancer treatment, increased substantially and is
causing great economic burden in Taiwan. Cancers of
the lung and female breast, and colorectal cancer,
accounted for the most used targeted therapies.
Between 2009 and 2012, use and costs of targeted
therapies increased almost threefold (tables 1 and 2),
with steep growth since the third quarter of 2011
(ﬁgure 1). This trend is likely to continue in the future.
We found that the average cost per prescription of tar-
geted therapies was much higher than that of other
classes of antineoplastic agents, with a 3–10-fold differ-
ence in 2012. It is important that policymakers revisit
the pricing and reimbursement structures for these
Figure 2 Use (A) and costs (B) of targeted therapies by 20 cancer types (2009–2012). (A) Distribution ratios of prescription
volume for targeted therapies by cancer type. (B) Distribution ratios of costs for targeted therapies by cancer type.
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Table 4 Use and costs of targeted therapies by cancer type over time
Cancer type
Distribution ratio based on prescription volume (%) Distribution ratio of costs (%)
2009 2010 2011 2012
2009–2012
overall
2009–2012
growth rate 2009 2010 2011 2012
2009–2012
overall
2009–2012
growth rate
01 Lung 51.87 45.94 43.03 42.18 44.64 −9.68 39.55 28.79 25.48 25.24 28.26 −14.32
02 Female breast 11.71 18.62 18.47 15.95 16.49 4.24 20.91 31.45 30.60 24.78 27.18 3.87
03 Colorectal 9.52 7.01 12.32 15.62 12.11 6.10 12.12 8.65 13.13 16.29 13.16 4.16
04 Lymphoma 17.87 14.92 11.84 8.50 12.09 −9.37 15.24 11.63 9.96 7.49 10.23 −7.74
05 Liver 0.24 0.23 0.28 3.93 1.66 3.69 0.25 0.22 0.28 5.65 2.22 5.40
06 Leukaemia 1.75 2.81 3.66 3.57 3.17 1.83 2.50 4.80 5.60 5.56 4.94 3.06
07 Urinary 0.43 2.70 3.01 2.82 2.48 2.39 0.52 4.53 5.25 4.95 4.26 4.43
08 Multiple myeloma 1.92 2.11 2.39 3.07 2.52 1.15 3.37 3.19 3.60 4.45 3.79 1.08
09 Oral/pharyngeal 1.58 2.40 2.01 1.48 1.82 −0.10 1.59 2.43 2.03 1.57 1.88 −0.03
10 Stomach 0.97 0.77 0.62 0.58 0.69 −0.39 1.28 1.14 1.04 0.93 1.06 −0.35
11 Brain 0.34 0.24 0.27 0.48 0.36 0.14 0.27 0.18 0.17 0.60 0.34 0.33
12 Small intestine and
duodenum
0.43 0.51 0.43 0.34 0.41 −0.09 0.80 0.99 0.90 0.74 0.85 −0.06
13 Bone 0.45 0.48 0.44 0.33 0.41 −0.12 0.65 0.74 0.80 0.57 0.68 −0.08
14 Thyroid 0.15 0.13 0.22 0.22 0.19 0.07 0.20 0.14 0.20 0.20 0.19 0.00
15 Prostate 0.18 0.23 0.19 0.22 0.20 0.04 0.16 0.27 0.18 0.22 0.21 0.06
16 Larynx 0.24 0.48 0.41 0.26 0.34 0.02 0.26 0.47 0.41 0.27 0.35 0.01
17 Pancreas 0.01 0.02 0.10 0.14 0.09 0.13 0.01 0.02 0.06 0.20 0.10 0.19
18 Cervix 0.16 0.20 0.14 0.11 0.14 −0.05 0.16 0.17 0.13 0.10 0.13 −0.05
19 Oesophagus 0.09 0.12 0.13 0.09 0.11 0.01 0.07 0.12 0.13 0.10 0.11 0.03
20 Ovary 0.10 0.08 0.05 0.10 0.08 0.00 0.09 0.08 0.05 0.08 0.07 −0.01
Total 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
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medicines because prices for all targeted therapies are
high even for those that offer limited clinical beneﬁts.
Our study adds to the literature stating that the avail-
ability and increasing use of innovative but expensive tar-
geted therapies are major drivers of increases in
pharmaceutical expenditures.25 26 We showed that the
costs of targeted therapies accounted for almost 42% of
expenditures for all antineoplastic agents in Taiwan in
2012. Monoclonal antibodies and protein kinase inhibi-
tors contributed the most (23.84% and 16.12% of costs
for antineoplastic agents). Targeted therapies also dom-
inate cancer drug expenditures in other countries, for
example, they accounted for 63% of all cancer drug
expenditures in 2011 in the commercially insured US
population.46
The high cost of targeted therapies is a barrier to
access targeted therapies for treatment of cancer.28 It is
important to ensure patient access to effective targeted
therapies without overspending the healthcare budget,
given their clinical beneﬁts. Many experts propose that
dialogue involving all parties concerned (eg, policy-
makers, industry, clinicians, patients and the general
public) is needed to address the reasons behind high
prices of cancer drugs and to provide solutions to
reduce prices. Experts also propose that drug prices
should reﬂect objective measures of beneﬁt, but should
not exceed values that could harm patients and soci-
eties.27 47 Overall, strategies for future management of
new cancer medicines might include raising the bar for
clinical trials by deﬁning clinically meaningful out-
comes,48 establishing minimum effectiveness levels for
new cancer medicines,15 24 generating a list of essential
medicines for patients with cancer, discussing potential
future measures to fund new innovative cancer medi-
cines without potentially compromising patients/health-
care systems,23 and determining the proportion of
healthcare resources spent on cancer medicines based
on the consideration of their balance of costs and
outcomes.47
There are some limitations to this study. First, this
study aimed to examine recent trends in drug utilisation
and expenditures for cancer treatment and to estimate
the market shares by prescription volume and costs for
targeted therapies in Taiwan; our analysis only examined
data up to 2012, as these were the more recent data
available at the time of the analysis. We used aggregate
data and did not analyse patient-level data, to under-
stand the inﬂuence of patient characteristics on treat-
ment selection and clinical outcomes of treatments.
Additionally, this study did not examine the complex
patterns of drug use, such as use of combination treat-
ments, and targeted therapy adherence and persistence,
again because of the lack of patient-level data. This study
examined economic burden of targeted therapies from
the perspective of the healthcare system; we did not
examine patient contribution to drug costs in Taiwan;
this warrants a separate study. Further, we did not char-
acterise changes in the policy environment in Taiwan
during the study period. Examples include the launch
of new, competing targeted therapies, publication of
large randomised clinical trial results, changes in clinical
guidelines or reimbursement policies, and patient and
provider factors (eg, patient clinical history, physician’s
knowledge and preference). Future studies are needed
to examine the impact of changes in policy and the clin-
ical environment, on use of targeted therapies. Finally,
various types of restrictions (eg, prior authorisations)
have been applied for many high-cost targeted therapies
for cancer in Taiwan.49 How these restrictions impact
cancer care and outcomes should be studied.
CONCLUSION
Targeted therapies have played an increasing and more
important role in treatment of all malignancies in
Taiwan, and are likely to pose substantial economic
burden in the future. Cancers of the lung and female
breast, and colorectal cancer, were identiﬁed as the
main drivers of use and costs of targeted therapies in
recent years. Policymakers, industry, clinicians and
patients need to communicate and develop strategies to
enable access to effective (and cost-effective) targeted
therapies without overspending the healthcare budget.
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